Bharat Ankit, Cunningham Scott A, Scott Budinger G R, Kreisel Daniel, DeWet Charl J, Gelman Andrew E, Waites Ken, Crabb Donna, Xiao Li, Bhorade Sangeeta, Ambalavanan Namasivayam, Dilling Daniel F, Lowery Erin M, Astor Todd, Hachem Ramsey, Krupnick Alexander S, DeCamp Malcolm M, Ison Michael G, Patel Robin
Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Mayo Clinic, Rochester, MN 55905, USA.
Sci Transl Med. 2015 Apr 22;7(284):284re3. doi: 10.1126/scitranslmed.aaa8419.
Hyperammonemia syndrome is a fatal complication affecting immunosuppressed patients. Frequently refractory to treatment, it is characterized by progressive elevations in serum ammonia of unknown etiology, ultimately leading to cerebral edema and death. In mammals, ammonia produced during amino acid metabolism is primarily cleared through the hepatic production of urea, which is eliminated in the kidney. Ureaplasma species, commensals of the urogenital tract, are Mollicutes dependent on urea hydrolysis to ammonia and carbon dioxide for energy production. We hypothesized that systemic infection with Ureaplasma species might pose a unique challenge to human ammonia metabolism by liberating free ammonia resulting in the hyperammonemia syndrome. We used polymerase chain reaction, specialized culture, and molecular resistance profiling to identify systemic Ureaplasma infection in lung transplant recipients with hyperammonemia syndrome, but did not detect it in any lung transplant recipients with normal ammonia concentrations. Administration of Ureaplasma-directed antimicrobials to patients with hyperammonemia syndrome resulted in biochemical and clinical resolution of the disorder. Relapse in one patient was accompanied by recurrent Ureaplasma bacteremia with antimicrobial resistance. Our results provide evidence supporting a causal relationship between Ureaplasma infection and hyperammonemia, suggesting a need to test for this organism and provide empiric antimicrobial treatment while awaiting microbiological confirmation.
高氨血症综合征是一种影响免疫抑制患者的致命并发症。它常常对治疗无效,其特征是血清氨水平不明原因地进行性升高,最终导致脑水肿和死亡。在哺乳动物中,氨基酸代谢过程中产生的氨主要通过肝脏合成尿素来清除,尿素在肾脏中排出。脲原体属是泌尿生殖道的共生菌,属于支原体,依赖尿素水解为氨和二氧化碳来产生能量。我们推测,脲原体属的全身感染可能通过释放游离氨对人体氨代谢构成独特挑战,从而导致高氨血症综合征。我们使用聚合酶链反应、特殊培养和分子耐药性分析来鉴定患有高氨血症综合征的肺移植受者中的脲原体全身感染,但在氨浓度正常的任何肺移植受者中均未检测到。对患有高氨血症综合征的患者使用针对脲原体的抗菌药物导致该疾病的生化和临床症状得到缓解。一名患者复发伴有复发性脲原体菌血症和抗菌药物耐药性。我们的结果提供了支持脲原体感染与高氨血症之间因果关系的证据,表明在等待微生物学确认时需要检测这种病原体并提供经验性抗菌治疗。